MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
156 M |
Market Cap[1] |
$ 1.16 B |
EBITDA (LTM) |
$ -103 M |
P/E (LTM) |
-21.145161 |
P/S (LTM) |
- |
EPS (LTM) |
-0.62 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MacroGenics
MGNX
|
$ 2.24 | -3.25 % | $ 141 M | Nasdaq Global Select Market | USA |
 |
ImmuCell Corporation
ICCC
|
$ 9.88 | -4.77 % | $ 89.2 M | Nasdaq Global Select Market | USA |
 |
Nuvation Bio
NUVB
|
$ 4.19 | -11.42 % | $ 1.43 B | NYSE | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.27 | -4.52 % | $ 179 B | NYSE |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.9 | -11.24 % | $ 13.8 M | Nasdaq Global Market | USA |
 |
NextCure
NXTC
|
$ 5.16 | -12.39 % | $ 14.7 M | Nasdaq Global Select Market | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 6.89 | -8.62 % | $ 599 M | Nasdaq Global Select Market | USA |
 |
Kymera Therapeutics
KYMR
|
$ 124.88 | -8.34 % | $ 10.6 B | Nasdaq Global Market | USA |
 |
Oragenics
OGEN
|
$ 0.34 | -9.47 % | $ 733 K | NYSE American | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.59 | -5.66 % | $ 337 M | Nasdaq Global Select Market | USA |
 |
Passage Bio
PASG
|
$ 3.44 | -2.14 % | $ 11 M | Nasdaq Global Select Market | USA |
 |
Vaxcyte
PCVX
|
$ 62.47 | -4.89 % | $ 8.5 B | Nasdaq Global Select Market | USA |
 |
Precigen
PGEN
|
$ 4.2 | -16.94 % | $ 1.31 B | Nasdaq Global Select Market | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.81 | -7.25 % | $ 4.85 M | Nasdaq Capital Market | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 262.42 | -7.85 % | $ 5.91 B | Nasdaq Global Select Market,SPB | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.55 | -12.99 % | $ 273 M | Nasdaq Global Select Market | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.34 | -5.32 % | $ 141 M | Nasdaq Global Market |  Niderland |
 |
Ocular Therapeutix
OCUL
|
$ 6.48 | -9.31 % | $ 1.21 B | Nasdaq Global Select Market | USA |
 |
PolyPid Ltd.
PYPD
|
$ 5.8 | -0.34 % | $ 94.8 M | Nasdaq Global Select Market |  Israel |
 |
Summit Therapeutics
SMMT
|
$ 14.17 | -12.37 % | $ 10.6 B | Nasdaq Global Select Market |  Britain |
 |
Outlook Therapeutics
OTLK
|
$ 0.44 | -4.63 % | $ 15.3 M | Nasdaq Global Select Market | USA |
 |
uniQure N.V.
QURE
|
$ 20.96 | -9.01 % | $ 1.21 B | Nasdaq Global Select Market | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 15.55 | -9.38 % | $ 1.53 B | Nasdaq Global Select Market,SPB | USA |
 |
Rafael Holdings
RFL
|
$ 1.06 | -4.5 % | $ 54.5 M | NYSE | USA |
 |
REGENXBIO
RGNX
|
$ 7.37 | -4.47 % | $ 380 M | Nasdaq Global Select Market,SPB | USA |
 |
Sanofi
SNY
|
$ 46.87 | -1.26 % | $ 57.2 B | Nasdaq Global Select Market |  France |
 |
Rigel Pharmaceuticals
RIGL
|
$ 45.56 | -11.17 % | $ 819 M | Nasdaq Global Select Market | USA |
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | USA |
 |
Генетико
GECO
|
- | - | - | MOEX |  Russia |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Tenax Therapeutics
TENX
|
$ 1.65 | -8.84 % | $ 64.7 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Scholar Rock Holding Corporation
SRRK
|
$ 45.27 | -1.78 % | $ 5.19 B | Nasdaq Global Select Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market | Britain |
|
Rezolute
RZLT
|
$ 3.65 | -7.95 % | $ 379 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 0.62 | -2.71 % | $ 66.1 M | Nasdaq Global Market | Britain |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | Germany |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | Germany |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.72 | 1.04 % | $ 1.16 B | Nasdaq Capital Market | Israel |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | China |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Seer
SEER
|
$ 1.63 | -4.12 % | $ 90.3 M | Nasdaq Global Select Market | USA |
 |
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | China |
 |
Trevi Therapeutics
TRVI
|
$ 12.8 | -8.47 % | $ 1.72 B | Nasdaq Global Market | USA |
|
Silence Therapeutics plc
SLN
|
$ 19.73 | -0.35 % | $ 2.8 B | Nasdaq Global Select Market | Britain |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.